Opendata, web and dolomites

Quality2Cells

TimeLapseReader for Quality Control of Immune Cells used for Cell-Based Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Quality2Cells project word cloud

Explore the words cloud of the Quality2Cells project. It provides you a very rough idea of what is the project "Quality2Cells" about.

provider    slides    freedom    regarding    cancer    ce    reagents    market    hundred    cured    combination    setting    tumours    strategy    patients    worldwide    kits    immune    cure    adverse    millions    entry    bench    motility    disruptive    20    timelapsereader    assuming    global    live    migration    version    complete    operate    types    treatment    cbt    validate    marking    transform    therapeutic    thousands    standardized    15    remaining    facilities    risks    explore    patient    plan    solution    ibidi    competitor    quality    inactive    difficult    cells    medicine    treat    automated    ready    consolidate    medical    expensive    elicit    instrument    cell    standard    migrating    serval    ctb    culture    final    enter    eminent    device    assays    qc    personalized    manufacturing    feasibility    reproducible    tests    approval    carriers    obtain    identification    efficient    regulatory    actively    player    strives    innovation    business    therapy   

Project "Quality2Cells" data sheet

The following table provides information about the project.

Coordinator
IBIDI GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG MARTINSRIED
postcode: 82152
website: www.ibidi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.ibidi.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBIDI GMBH DE (PLANEGG MARTINSRIED) coordinator 50˙000.00

Map

 Project objective

Cell-based therapy (CBT) for cure of difficult-to-treat cancer types is the most disruptive innovation in personalized medicine. However, patient-specific production of therapeutic immune cells is expensive and associated with remaining risks. In particular, it is known that only actively migrating immune cells are efficient against tumours cells, while inactive therapeutic cells can elicit adverse effects. Yet, there is no quality control (QC) regarding motility of therapeutic cells before patient treatment. The goal of the proposal is to promote an integrated bench-top instrument for reliable assessment of motility parameters in standardized cell culture carriers, i.e. the TimeLapseReader.

As leading provider of live cell migration assays ibidi strives to market a complete QC solution based on an automated instrument in combination with ready-to-use QC kits, slides and reagents. The TimeLapseReader will allow robust and reproducible migration tests in manufacturing facilities and set a new standard for QC of immune cell in CBT.

In Phase 1 the feasibility study will explore key parameters for QC in the most relevant therapeutic cell types and the best market entry strategy. Objectives include: • Identification of relevant QC parameters for therapeutic cells. • Setting up the business plan including competitor and freedom-to-operate analysis. • Strategy to obtain regulatory approval / CE-Marking for the final device version.

Expected impact is eminent as CBT is going to enter the medical market with serval hundred to thousands of patients treated worldwide per year. It is expected, that up to 20% of all cancer patients can be cured with CTB within 10-15 years assuming serval millions QC per year. ibidi will apply for funding to validate QC tests in a Phase 2 proposal. Phase 2 will consolidate the technology and transform ibidi into a global player of medical QC in the CBT field.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUALITY2CELLS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QUALITY2CELLS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More